The circulating blood platelet is produced by the bone marrow megkarocyte. In response to a decrease in the platelet count, megryocytes increase in number and ploidy. Although this feedback loop has long been thought to be medlated by a circulating hematopoletic factor, no such factor has been purified. Using a model ofthrombocytopenia in sheep, we have identified an active substance called megapoetin, which simulated an increase in the number and ploldy of meg-karyocytes in bone marrow culture. Circulating levels of this factor could be quantified with this assay and were found to be Inversely proportional to the platelet count of the sheep. Megakaryocytes are unusual bone marrow cells, which are responsible for producing circulating blood platelets. Although comprising <0.25% of the bone marrow cells in most species, they have >10 times the volume of typical marrow cells (1, 2). In addition, megakaryocytes undergo a process known as endomitosis whereby they replicate their nuclei but fail to undergo cell division and thereby give rise to polyploid cells. In response to a decreased platelet count, the endomitotic rate increases (3, 4), higher ploidy megakaryocytes are formed, and the number of megakaryocytes may increase up to 3-fold (1). In contrast, in response to an elevated platelet count, the endomitotic rate decreases (3, 4), lower ploidy megakaryocytes are formed, and the number of megakaryocytes may decrease by 50%o (1).
ploidy. Although this feedback loop has long been thought to be medlated by a circulating hematopoletic factor, no such factor has been purified. Using a model ofthrombocytopenia in sheep, we have identified an active substance called megapoetin, which simulated an increase in the number and ploldy of meg-karyocytes in bone marrow culture. Circulating levels of this factor could be quantified with this assay and were found to be Inversely proportional to the platelet count of the sheep.
Levels increased from <0.26 pM in normal sheep to 25-40 pM in thrombocytopenic sheep. From large amounts of thrombocytopenic sheep plasma we have purified a 31,200-Da protein and found that it retained the ability to smulate both megakaryocyte number and ploldy in vitro. Injection of partially purified tin into rats stimulated a 24% increase in megakaryocyte number and a 60% increase in mean ploldy as well as a 77% increase in the platelet count. Sheep platelets bound megapoletin and the amount of platelets requlred to eiminate half the activity in vitro was close to the amount asociated with this same level of activity in vivo. We believe that megapoletin is the physlologicaily relevant mediator of megakaryocyte growth and platelet production. Moreover, our data suggest that the level ofmegapoletin is directly determined by the ability of platelets to remove megapoletin from the circulation.
Megakaryocytes are unusual bone marrow cells, which are responsible for producing circulating blood platelets. Although comprising <0.25% of the bone marrow cells in most species, they have >10 times the volume of typical marrow cells (1, 2) . In addition, megakaryocytes undergo a process known as endomitosis whereby they replicate their nuclei but fail to undergo cell division and thereby give rise to polyploid cells. In response to a decreased platelet count, the endomitotic rate increases (3, 4) , higher ploidy megakaryocytes are formed, and the number of megakaryocytes may increase up to 3-fold (1) . In contrast, in response to an elevated platelet count, the endomitotic rate decreases (3, 4) , lower ploidy megakaryocytes are formed, and the number of megakaryocytes may decrease by 50%o (1) . The physiological feedback mechanism by which the mass of circulating platelets regulates the endomitotic rate and number of bone marrow megakaryocytes is not known. A circulating thrombopoietic factor has long been assumed to be involved but to date no such factor has been purified. Moreover, none of the recombinant cytokines with thrombopoietic activity, such as interleukin 6 (5) , is known to be involved in mediating this physiological feedback loop.
To characterize this putative thrombopoietic factor, we have analyzed the physiological relationship between the bone marrow megakaryocytes and the circulating platelets. We have found that the magnitude of the changes in the number and ploidy of megakaryocytes was inversely and proportionally related to the circulating platelet mass (3) and that megakaryocyte number and ploidy were therefore markers of this feedback loop in vivo. We next developed a bone marrow assay in which increases in the number and ploidy of megakaryocytes in vitro (6) were used to identify an active substance in thrombocytopenic plasma that we have named megapoietin (3, 7) . Levels of megapoietin could be quantified with this assay and were inversely proportional to the platelet mass (3, 7) . Once elevated in thrombocytopenic animals, the megapoietin level could be reduced to normal by transfusion of platelets (3).
These results suggested that megapoietin was an ideal candidate to be the thrombopoietic factor mediating the feedback loop between the circulating platelets and the bone marrow megakaryocytes. We now report the development of a sheep model of thrombocytopenia, which has allowed us to purify megapoietin from thrombocytopenic plasma and to elucidate the characteristics of the purified protein. (3, 6, 7, 9) .
MATERIALS AND METHODS
Megapoietin Purification. All procedures were carried out at 4TC. The sheep plasma was thawed and fibrinogen was precipitated at a final concentration of 7.5% polyethylene glycol (Mr 3350; J. T. Baker, Jackson, TN). The supernatant was then loaded onto a CM Sepharose (Pharmacia) column (35 x 30 cm) and the adsorbed protein was step-eluted with 300 mM NaCl/50 mM NaH2PO4, pH 6. The harvested protein was then reapplied to a CM Sepharose column (50 mm x 100 cm) at 50 mM NaCl/50 mM NaH2PO4, pH 6, and eluted with a linear NaCl gradient in the same buffer system. The fractions containing megapoietin activity were pooled, charged to a DEAE-Sepharose column (50 mm x 100 cm; Pharmacia), and eluted with a linear NaCl gradient in 20 mM Tris-HCl (pH 8.6 ). The fractions possessing megapoietin activity were pooled, concentrated, and applied to a ceramic hydroxylapatite column (19 mm x 10 cm; Bio-Rad) at 100 mM NaCl/10 mM KH2PO4, pH 6.8 . The unadsorbed protein was reapplied to a ceramic hydroxylapatite column (7.8 mm x 10 cm; Bio-Rad) in 20 mM NaCl/10 mM KH2PO4, pH 6.8, and bound protein was step-eluted with 0.18 M KH2PO4 (pH 6.8) . The fractions exhibiting megapoietin activity were concentrated with a 1-ml Mono S column (Pharmacia), charged to a 1-ml wheat germ agglutinin-Sepharose column (Pharmacia), and step-eluted with chitodiose (4 mg/ml in 0.125 M NaCl/50 mM NaH2PO4, pH 7.5). The material with megapoietin activity was bound to a 1-ml heparin Sepharose column (Pharmacia) and eluted with a linear NaCl gradient in 25 mM NaH2PO4 (pH 7.5). The fractions with megapoietin activity were pooled and applied to a Tosohaas TMS-250 column (7.8 mm x 7.5 cm; The Nest Group, Southborough, MA), and bound proteins were eluted with a gradient (10%!6 90% to 70%/30%) of acetonitrile/isopropanol (3:1)/ trifluoroacetic acid (0.1%). The material containing megapoietin activity was pooled and then filtered on a Tosohaas TSK G-3000 column (7.5 mm x 60 cm; The Nest Group, Southborough, MA) in 50% trifluoroacetic acid (0.1%)/50% acetonitrile/isopropanol (3:1).
Examination of Megapoietin Preparations at Different Stages of Purification. Protein preparations were labeled with 1251 and then analyzed by SDS/PAGE under reducing and nonreducing conditions as described by Laemmli (10) . The levels of megapoietin activity present in the various electrophoretic bands were assessed by slicing the nonreduced SDS gels, eluting the protein into Hanks' balanced salt solution containing 15% fetal bovine serum, and assaying for megapoietin in vitro as outlined above. The overall recovery of megapoietin activity from nonreduced SDS/PAGE was 13-22%.
TSK purified protein was digested with endoproteinase Lys-C (Boehringer Mannheim) at 37C for 24 h, the peptides were then separated on a C4 column (Vydac, no. 214TP52; Hesperia, CA), and the amino acid sequence of isolated peptides was obtained with the model 477A protein sequencer with on-line model 120 phenylthiohydantoin amino acid analyzer (Applied Biosystems).
RESULTS
Megapoietin Appeared in the Circulation of Thrombocytopenic Busufan-Treated Sheep. After administration of busulfan to 106 sheep, the normal platelet count (508,000 ± 86,000 platelets per A4) increased slightly by day 3 but by day 7 began to decline to its nadir (111,000 ± 63,000 platelets per y1) on days 16 and 17, a decrease to 23% ± 3% of normal (Fig. 1) . The WBC count also began to decline from normal (5919 ± 1179 WBC per p1) after day 7 and reached its nadir (2007 ± 1157 WBC per A1) on days 12-16, a drop to 34% ± 4% of normal. The hematocrit did not decline from normal (47 ± 6) until day 10, when it began to fall to its nadir (41 ± 9) on day 17, a decline to 90% ± 9%o of normal.
In six sheep, plasma samples were taken at frequent intervals for determination of megapoietin activity. Not until after day 7 did plasma samples stimulate the number and mean ploidy of megakaryocytes that grew in bone marrow culture (Fig. 1) . For all six sheep, the magitude of this stimulation was inversely proportional to the platelet count and peaked at the time the platelet count was at its nadir. Comparing the effect of plasma samples taken prior to busulfan treatment to those taken at the platelet nadir for all six sheep, the number ofmegakaryocytes produced in culture increased from 3203 ± 1656 to 6430 ± 1955, an average increase to 202% ± 97%. The mean ploidy increased from 10.8 Because megapoietin activity was destroyed by reducing agents, two aliquots of the final TSK product, one iodinated, were run unreduced in adjacent lanes on an SDS gel. The lane containing the labeled protein was subjected to autoradiography. The lane containing unlabeled protein was sliced and the eluted protein was tested for megapoietin activity. As shown in Fig. 2 , four labeled protein bands were seen. The 52,100-Da minor species contained no megapoietin activity, was absent when labeled by the chloramine-T method, and was not present in most other preparations. Megapoietin activity (Fig. 2) was associated with three proteins of41,600, 35,700, and 27,800 Da (unreduced). These three proteins contained 7%, 20%6, and 73%, respectively, of the total protein radioactivity and 5%, 16%, and 79%, respectively, of the megapoietin activity. In (Fig. 3A) increase in the number (from 10,076 ± 1121 to 15,505 ± 1577) and mean ploidy (from 10.4 The linear increase in mean ploidy in our bioassay was related to a logarithmic increase in megapoietin concentration ( Fig. 3B ) with a limit of detection of 1.67 pM. Over the same megapoietin concentrations, the number of megakaryocytes in culture showed an identical dose-response relationship and increased from 9245 ± 205 to 13,319 ± 1470.
When thrombocytopenic plasma was subsequently compared in culture with purified megapoietin, we estimated that it contained megapoietin at -25-40 pM and that normal plasma contained <0.25 pM.
In Vivo Effects of Megapoietin. When partially purified (310-fold through the DEAE-Sepharose step) megapoietin was injected into recipient rats (Fig. 4A) , the mean ploidy increased over time to a level comparable to that seen in rats made severely thrombocytopenic by injection of anti-platelet antibody (3). Changes in individual ploidy classes were apparent after 2 days and by 4 days (Fig. 4B) were comparable to those seen in severely thrombocytopenic rats. After 4 days, but not after 2 days, the percentage of megakaryocytes in the bone marrow increased from 0.128% ± 0.005% to 0.159% ± 0.023% (P < 0.05).
Although unchanged after 2 days of injection, after 4 days the platelet count (Fig. 4C) Another group of rats was injected for 4 days with partially purified megapoietin (Fig. 4D) . The platelet count began to increase on day 5, peaked at day 7, and then returned to normal. Again, there was no effect on the WBC count or hematocrit in the animals.
Sheep Platelets Bind to and Remove Megapoietin. When thrombocytopenic sheep plasma or plasma reconstituted with purified megapoietin was incubated with an amount of sheep platelets equal to that which would have been present in these plasmas in vivo in the absence ofthrombocytopenia, all of the megapoietin was removed (Fig. SA) . Because incubation of platelets with normal sheep plasma did not produce inhibition of the cultures (Fig. SA) or buffer (1.68 ml)) for 4 days thatched area) and the platelet counts were determined at interials (V). All data are presented -SD). Foi-A and B all differences between normal and MP-injected or Ti rats are statisticallx significant at P < 0.001 while all differences betiseen MP-injected and simultaneous buffer-injected rats are significant at P 0.0-5. rat platelets, but not purified rat erythrocytes or lymphocytes, also removed all the megapoietin.
When normal sheep plasma reconstituted with purified megapoietin was exposed to various amounts of sheep platelets so as to approximate in vitro different levels of thrombocytopenia, an increasing extent of megapoietin removal was observed as a function of platelet addition (Fig. 5B) . At a platelet count of 24% of normal, half of the apparent megapoietin activity was removed as judged by mean ploidy. This relationship should be compared with the six thrombocytopenic sheep described in Fig. 1 in which the relative levels of megapoietin increased in vivo over time as the platelet count declined (Fig. SB) . At a platelet count of 43% of normal, the apparent megapoietin activity as determined by mean ploidy was half-maximal, close to the platelet count that produced half-maximal removal in vitro.
DISCUSSION
The identification and purification of the physiologically relevant thrombopoietic factor that mediates platelet production by megakaryocytes have been elusive. We have found that thrombocytopenic plasma contains an active substance called megapoietin, which stimulates the number and ploidy of megakaryocytes that grow in bone marrow culture (3) . Using this assay, we have determined the time course of megapoietin's appearance in the circulation and shown that its activity has all the characteristics expected of a physiological regulator. We have now created a sheep model of thrombocytopenia, which has provided adequate quantities of thrombocytopenic plasma to permit purification of what we believe is the principle humoral regulator of megakaryocyte endomitosis and platelet production.
Busulfan produced severe thrombocytopenia after 12-15 days with only modest neutropenia and anemia. Plasma from these thrombocytopenic sheep contained megapoietin, since it stimulated an increase in the number and ploidy of megakaryocytes in our bone marrow culture system. As the platelet count declined, the extent of stimulation of the mean ploidy and the number of megakaryocytes in our assay increased proportionally. This reflected an average increase in megapoietin concentration of >100-fold, from 0.25 to 25 pM.
Megapoietin has been purified to homogeneity and is a glycoprotein composed of two species, a major protein of 31,200 Da and a minor protein of 36,700 Da, both with the same specific activity. Like the initially described megapoietin activity (3, 7, 9) , the purified megapoietin protein stimulated both the number and endomitotic rate of megakaryocytes in vitro. Although sufficient quantities of the final purified product were not available for injection into animals, partially purified protein from thrombocytopenic but not from normal sheep plasma stimulated an increase in the megakaryocyte number, ploidy, and platelet count when injected into rats. Megakaryocyte ploidy increased by day 3 and was maximal by day 5. The number of megakaryocytes increased by day 5 and was accompanied by an increase in platelet count, which became maximal on day 7. The extent of these megakaryocyte changes in the megapoietin-treated rats was indistinguishable from what we have found in rat bone marrow after induction of severe thrombocytopenia. (7) or an equivalent amount ofbuffer (-) were incubated for 1 h at room temperature with normal and thrombocytopenic (TC) sheep plasma as well as with normal sheep plasma into which purified MP had been added (to a level -75% that found in the TC plasma). After centrifugation twice at 3000 x g for 15 min, the supernatants were assayed for residual MP activity. Relative changes in mean ploidy (±SD) were 6 . Proposed mechanism by which megapoietin regulates megakaryocyte growth and platelet production.
was strikingly close to that platelet count required in vivo for the half-maximal appearance of megapoietin in the circulation. The small differences between these in vitro and in vivo platelet counts can be accounted for by taking into consideration some effect of the older age or diminished function of the platelets in vivo.
Our data show that megapoietin is the physiologically relevant protein that mediates the feedback loop between the circulating platelets and the bone marrow megakaryocytes. Although the site of its production is not yet known, the effective circulating level of megapoietin is regulated by the ambient platelet mass. With a decline in platelet mass (or possibly a decline in the platelet binding of megapoietin due to increased age or decreased function of platelets), circulating levels of megapoietin increase and stimulate an increase in megakaryocyte number and ploidy, which then increase the production of platelets (see the right side of Fig.  6 ). With an increase in platelet mass (or possibly an increase in binding of megapoietin due to decreased age or increased function of platelets) circulating megapoietin levels decline and the number and ploidy of bone marrow megakaryocytes decrease with a consequent decrease in platelet production (see the left side of Fig. 6 ). The availability of purified megapoietin should now allow us to explore further the implications of this model. This paper was submitted several weeks before the identification of the human c-mpl ligand was reported (12) . The amino acid sequences of the three megapoietin peptides described above are >70% identical to residues 122-138, 153-173, and 173-198 in the c-mpl ligand sequence. This sequence homology and the virtually identical range of biological activities demonstrate that megapoietin is the same as the c-mpl ligand.
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